FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Accuracy is approximately 90% with careful distinction between core biopsies and fine needle biopsy with the former being more accurate. While some argue renal biopsy will not alter treatment Dr. Finelli argue it can due to identification of benign histology such as Type I papillary renal cell carcinoma which may be observed. Concordance with surgery is over 90% comparing biopsy to final surgical pathology among those that undergo definitive surgery. Moreover, with the advent of proteomic and genomic evaluation of tumors research have shown that core biopsies can be banked for future research purposes with data at their institution demonstrating sufficient tissue available in the biopsies for that purpose.
World Urological Oncology Federation Symposium at the SIU Congress 2016 - October 20 - 23, 2016 – Buenos Aires, Argentina
Written By: Stephen B. Williams, M.D., Assistant Professor in Urology, The University of Texas Medical Branch, Galveston, TX. and Ashish Kamat, M.D. Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX.